Please wait a minute...
浙江大学学报(医学版)  2017, Vol. 46 Issue (5): 563-569    DOI: 10.3785/j.issn.1008-9292.2017.10.18
王梦嫣, 朱彪
浙江大学医学院附属第一医院感染病中心 传染病诊治国家重点实验室 感染病诊治 协同创新中心, 浙江 杭州 310003
Research progress on genes mutations related to sulfa drug resistance in Pneumocystis jirovecii
WANG Mengyan, ZHU Biao
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Department of Infection Diseases, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
 全文: PDF(946 KB)  


关键词: 肺囊虫性/病理生理学突变基因四氢叶酸脱氢酶综述肺炎磺胺类/药理学抗药性细菌/遗传学    

Pneumocystis jirovecii pneumonia is an opportunistic infection among immunocompromised people. Studies have found that the increased resistance to sulfa drugs of Pneumocystis jirovecii may be associated with the mutation of dihydropteroate synthase (DHPS) gene and dihydrofolate reductase (DHFR) genes, but the mechanism is still unclear. The mutation of DHPS and DHFR genes may be the result of sulfa drugs selection or spontaneous genetic polymorphism, and it can be acquired from person-to-person transmission. This article reviews the cause, molecular epidemiology of DHPS and DHFR gene mutation, and the relationship between DHPS and DHFR gene mutation and clinical outcomes.

Key words: Drug resistance,bacterial/genetics    Pneumonia,pneumocystis/physiopathology    Tetrahydrofolate dehydrogenase    Sulfonamides/pharmacology    Genes    Mutation    Review
收稿日期: 2017-02-20 出版日期: 2017-10-25
CLC:  R379.9  


通讯作者: 朱彪(1965-),男,博士,主任医师,硕士生导师,主要从事艾滋病相关研究;;     E-mail:
作者简介: 王梦嫣(1993-),女,硕士研究生,主要从事艾滋病相关研究;;
E-mail Alert


王梦嫣 等. 耶氏肺孢子菌对磺胺类药物耐药相关基因突变的研究进展[J]. 浙江大学学报(医学版), 2017, 46(5): 563-569.

WANG Mengyan, ZHU Biao. Research progress on genes mutations related to sulfa drug resistance in Pneumocystis jirovecii. Journal of ZheJiang University(Medical Science), 2017, 46(5): 563-569.


[1] HUANG L, CROTHERS K, ATZORI C, et al. Dihydropteroate synthase gene mutations in pneumocystis and sulfa resistance[J]. Emerg Infect Dis,2004,10(10):1721-1728.
[2] MESHNICKS R. Drug-resistant pneumocystis carinii[J]. Lancet,1999,354(9187):1318-1319.
[3] HELWEG-LARSEN J, BENFIELD T L, EUGEN-OLSENJ,et al.Effects of mutations in pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia[J]. Lancet,1999,354(9187):1347-1351.
[4] TAYLOR S M, MESHNICK S R, WORODRIA W, et al. Low prevalence of pneumocystis pneumonia (PCP) but high prevalence of pneumocystis dihydropteroate synthase (DHPS) gene mutations in HIV-infected persons in Uganda[J/OL]. PLoS One,2012,7(11):e49991.
[5] HUANG L, WELSH D A, MILLER R F, et al. Pneumocystis jirovecii dihydropteroate synthase gene mutations and human immunodeficiency virus-associated pneumocystis pneumonia[J]. J Eukaryot Microbiol,2006,53 Suppl 1:S114-S116.
[6] HAUSER P M, NAHIMANA A, TAFFE P, et al. Interhuman transmission as a potential key parameter for geographical variation in the prevalence of pneumocystis jirovecii dihydropteroate synthase mutations[J]. Clin Infect Dis,2010,51(4):e28-e33.
[7] DINI L, DU P M, FREAN J, et al. High prevalence of dihydropteroate synthase mutations in Pneumocystis jirovecii isolated from patients with pneumocystis pneumonia in South Africa[J]. J Clin Microbiol,2010,48(6):2016-2021.
[8] OGUIKE M C, FALADE C O, SHU E, et al. Molecular determinants of sulfadoxine-pyrimethamine resistance in plasmodium falciparum in Nigeria and the regional emergence of DHPS 431V[J]. Int J Parasitol Drugs Drug Resist,2016,6(3):220-229.
[9] PORNTHANAKASEM W, RIANGRUNGROJ P, CHITNUMSUB P, et al. Role of plasmodium vivax dihydropteroate synthase polymorphisms in sulfa drug resistance[J]. Antimicrob Agents Chemother,2016,60(8):4453-4463.
[10] QUEENER S F, CODY V, PACE J, et al. Trimethoprim resistance of dihydrofolate reductase variants from clinical isolates of pneumocystis jirovecii[J]. Antimicrob Agents Chemother,2013,57(10):4990-4998.
[11] NAHIMANA A, RABODONIRINA M, BILLE J, et al. Mutations of Pneumocystis jirovecii dihydrofolate reductase associated with failure of prophylaxis[J]. Antimicrob Agents Chemother,2004,48(11):4301-4305.
[12] PONCE C A, CHABÉ M, GEORGE C, et al. High Prevalence of pneumocystis jirovecii dihydropteroate synthase gene mutations in patients with a first episode of pneumocystis pneumonia in Santiago, Chile, and clinical response to trimethoprim-sulfamethoxazole therapy[J]. Antimicrob Agents Chemother,2017,61(2).
[13] MONROY-VACA E X, DE ARMAS Y, ILLNAIT-ZARAGOZÍM T, et al. Prevalence and genotype distribution of pneumocystis jirovecii in Cuban infants and toddlers with whooping cough[J]. J Clin Microbiol,2014,52(1):45-51.
[14] WISSMANN G, MORILLA R, FRIAZA V, et al. Human reservoirs of pneumocystis[J]. Enferm Infecc Microbiol Clin,2010,28(1):38-43.
[15] GIANELLA S, HAEBERLI L, JOOS B, et al. Molecular evidence of interhuman transmission in an outbreak of pneumocystis jirovecii pneumonia among renal transplant recipients[J]. Transpl Infect Dis,2010,12(1):1-10.
[16] ROSTVED A A, SASSI M, KURTZHALS J A, et al. Outbreak of pneumocystis pneumonia in renal and liver transplant patients caused by genotypically distinct strains of pneumocystis jirovecii[J]. Transplantation,2013,96(9):834-842.
[17] CHOUKRI F, MENOTTI J, SARFATI C, et al. Quantification and spread of pneumocystis jirovecii in the surrounding air of patients with Pneumocystis pneumonia[J]. Clin Infect Dis,2010,51(3):259-265.
[18] DAMIANI C, CHOUKRI F, LE G S, et al. Possible nosocomial transmission of pneumocystis jirovecii[J]. Emerg Infect Dis,2012,18(5):877-878.
[19] VALADE S, AZOULAY E, DAMIANI C, et al. Pneumocystis jirovecii airborne transmission between critically ill patients and health care workers[J]. Intensive Care Med,2015,41(9):1716-1718.
[20] RABODONIRINA M, VAILLANT L, TAFFÉ P, et al. Pneumocystis jirovecii genotype associated with increased death rate of HIV-infected patients with pneumonia[J]. Emerg Infect Dis,2013,19(1):21-28.
[21] LONG Y, ZHANG C, SU L, et al. Pneumocystis jirovecii dihydropteroate synthase gene mutations in a group of HIV-negative immunocompromised patients with Pneumocystis pneumonia[J]. Exp Ther Med,2014,8(6):1825-1830.
[22] DIMONTE S, BERRILLI F, D'ORAZI C, et al. Molecular analysis based on mtLSU-rRNA and DHPS sequences of pneumocystis jirovecii from immunocompromised and immunocompetent patients in Italy[J]. Infect Genet Evol,2013,14:68-72.
[23] COSTA M C, ESTEVES F, ANTUNES F, et al. Genetic characterization of the dihydrofolate reductase gene of pneumocystis jirovecii isolates from Portugal[J]. J Antimicrob Chemother,2006,58(6):1246-1249.
[24] DENG X, ZHUO L, LAN Y, et al. Mutational analysis of pneumocystis jirovecii dihydropteroate synthase and dihydrofolate reductase genes in HIV-infected patients in China[J]. J Clin Microbiol,2014,52(11):4017-4019.
[25] MANE A, GUJAR P, CHANDRA J, et al. Pneumocystis jirovecii infection and the associated dihydropteroate synthase (DHPS) and dihydrofolate reductase (DHFR) mutations in HIV-positive individuals from Pune, India[J]. Mycopathologia,2015,179(1-2):141-145.
[26] PAROBEK C M, JIANG L Y, PATEL J C, et al. Multilocus microsatellite genotyping array for investigation of genetic epidemiology of pneumocystis jirovecii[J]. J Clin Microbiol,2014,52(5):1391-1399.
[27] LE G S, DAMIANI C, PERROT M, et al. Circulation of pneumocystis dihydropteroate synthase mutants in France[J]. Diagn Microbiol Infect Dis,2012,74(2):119-124.
[28] MAGNE D, ANGOULVANT A, BOTTEREL F, et al. Pneumocystosis:a network survey in the Paris area 2003-2008[J]. Eur J Clin Microbiol Infect Dis,2011,30(5):673-675.
[29] ALVAREZ-MARTÍNEZ M J, MIRÓ J M, VALLS M E, et al. Prevalence of dihydropteroate synthase genotypes before and after the introduction of combined antiretroviral therapy and their influence on the outcome of pneumocystis pneumonia in HIV-1-infected patients[J]. Diagn Microbiol Infect Dis,2010,68(1):60-65.
[30] SHEIKHOLESLAMI M F, SADRAEI J, FARNIA P, et al. Dihydropteroate synthase gene mutation rates in pneumocystis jirovecii strains obtained from Iranian HIV-positive and non-HIV-positive patients[J]. Med Mycol,2015,53(4):361-368.
[31] BESER J, DINI L, BOTERO-KLEIVEN S, et al. Absence of dihydropteroate synthase gene mutations in pneumocystis jirovecii isolated from Swedish patients[J]. Med Mycol,2012,50(3):320-323.
[32] YOON C, SUBRAMANIAN A, CHI A, et al. Dihydropteroate synthase mutations in pneumocystis pneumonia:impact of applying different definitions of prophylaxis, mortality endpoints and mutant in a single cohort[J]. Med Mycol,2013,51(6):568-575.
[33] ALVAREZ-MARTÍNEZ M J, MORENO A, MIRÓ J M, et al. Pneumocystis jirovecii pneumonia in Spanish HIV-infected patients in the combined antiretroviral therapy era:prevalence of dihydropteroate synthase mutations and prognostic factors of mortality[J]. Diagn Microbiol Infect Dis,2008,62(1):34-43
[34] MUÑOZ C, ZULUAGA A, RESTREPO A, et al. Molecular diagnosis and detection of pneumocystis jirovecii DHPS and DHFR genotypes in respiratory specimens from Colombian patients[J]. Diagn Microbiol Infect Dis,2012,72(3):204-213.
[35] KIM T, LEE S O, HONG H L, et al. Clinical characteristics of hospital-onset pneumocystis pneumonia and genotypes of pneumocystis jirovecii in a single tertiary centre in Korea[J]. BMC Infect Dis,2015,15:102.
[36] SINGH Y, MIRDHA B R, GULERIA R, et al. Molecular detection of DHFR gene polymorphisms in pneumocystis jirovecii isolates from Indian patients[J]. J Infect Dev Ctries,2015,9(11):1250-1256.
[37] SIRIPATTANAPIPONG S, LEELAYOOVA S, MUNGTHIN M, et al. Study of DHPS and DHFR genes of pneumocystis jirovecii in Thai HIV-infected patients[J]. Med Mycol,2008,46(4):389-392.
[38] NAGAMORI K, KATAYAMA T, KUMAGAI M. A case of cutaneous myiasis due to dermatobia hominis in Japan[J]. J Infect Chemother,2007,13(4):255-257.
[39] MONTESINOS I, DELFORGE M L, AJJAHAM F, et al. Evaluation of a new commercial real-time PCR assay for diagnosis of pneumocystis jirovecii pneumonia and identification of dihydropteroate synthase (DHPS) mutations[J]. Diagn Microbiol Infect Dis,2017,87(1):32-36.
[40] VAN HAL S J, GILGADO F, DOYLE T, et al. Clinical significance and phylogenetic relationship of novel Australian pneumocystis jirovecii genotypes[J]. J Clin Microbiol,2009,47(6):1818-1823.
[41] MOUKHLIS R, BOYER J, LACUBE P, et al. Linking pneumocystis jiroveci sulfamethoxazole resistance to the alleles of the DHPS gene using functional complementation in saccharomyces cerevisiae[J]. Clin Microbiol Infect,2010,16(5):501-507.
[42] CODY V, PACE J, PIRAINO J, et al. Crystallographic analysis reveals a novel second binding site for trimethoprim in active site double mutants of human dihydrofolate reductase[J]. J Struct Biol,2011,176(1):52-59.
[43] CODY V, PACE J, QUEENER S F, et al. Kinetic and structural analysis for potent antifolate inhibition of pneumocystis jirovecii, pneumocystis carinii, and human dihydrofolate reductases and their active-site variants[J]. Antimicrob Agents Chemother,2013,57(6):2669-2677.
[1] 许晶晶 等. 影像学在肿瘤精准医疗时代的机遇和挑战[J]. 浙江大学学报(医学版), 2017, 46(5): 455-461.
[2] 潘静颖 等. PET-CT与乳腺癌分子病理分型、治疗反应及预后的相关性研究进展[J]. 浙江大学学报(医学版), 2017, 46(5): 473-480.
[3] 张思影 等. CT和磁共振参数反应图在肿瘤精准疗效评估中的研究进展[J]. 浙江大学学报(医学版), 2017, 46(5): 468-472.
[4] 潘瑶 等. 胰腺癌的影像学精准诊断与评估[J]. 浙江大学学报(医学版), 2017, 46(5): 462-467.
[5] 董飞 等. 磁共振成像强化信号特征预测胶质母细胞瘤EGFR基因扩增状态的影像组学研究[J]. 浙江大学学报(医学版), 2017, 46(5): 492-497.
[6] 任晓梅 等. 低盐饮食对犬类心脏组织基因表达的影响[J]. 浙江大学学报(医学版), 2017, 46(4): 433-438.
[7] 李钰 等. 长链非编码RNA RP11-770J1.3和跨膜蛋白25对紫杉醇耐药人乳腺癌细胞株耐药性的影响[J]. 浙江大学学报(医学版), 2017, 46(4): 364-370.
[8] 葛玉梅 等. 解甘露醇罗尔斯顿菌的耐药性和原卟啉亚铁螯合酶毒力因子研究[J]. 浙江大学学报(医学版), 2017, 46(4): 413-420.
[9] 李艳蝶 等. NLRP3炎症小体与儿童自身炎症性疾病研究进展[J]. 浙江大学学报(医学版), 2017, 46(4): 449-453.
[10] 陈达华 等. CRISPR/Cas9基因编辑技术构建靶向敲除小鼠微小RNA-101a基因的一体化载体系统[J]. 浙江大学学报(医学版), 2017, 46(4): 427-432.
[11] 沈丹 等. 多囊卵巢综合征患者子代发生的远期改变[J]. 浙江大学学报(医学版), 2017, 46(3): 300-304.
[12] 傅晓华 等. 棕色脂肪组织及其与多囊卵巢综合征关系的研究进展[J]. 浙江大学学报(医学版), 2017, 46(3): 315-320.
[13] 傅燕玲 等. 肽类激素Kisspeptin在生殖内分泌领域的应用前景[J]. 浙江大学学报(医学版), 2017, 46(3): 328-333.
[14] 钱叶青 等. 高通量测序技术在临床遗传学中的应用[J]. 浙江大学学报(医学版), 2017, 46(3): 334-337.
[15] 王丽雅 等. 借助辅助生殖技术出生子代的安全性研究进展[J]. 浙江大学学报(医学版), 2017, 46(3): 279-284.